ChinRe-I, et al. “Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (CtDNA).” Molecular Diagnosis & Therapy, Vol. 23, No. 3, 2Apr.2019, pp. 311–331, 10.1007/s40291-019-00390-5. Accessed July 6, 2022.
2.
LarribèreLionel, and MartensUwe M.. “Advantages and Challenges of Using CtDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors.” Cancers, Vol. 13, No. 22, 14Nov.2021, p. 5698, 10.3390/cancers13225698. Accessed Feb. 12, 2022.
3.
HonoréNatasha, et al. “Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact.” Cancers, Vol. 13, No. 21, Oct.26, 2021, p. 5364, 10.3390/cancers13215364. Accessed Apr. 14, 2022.
4.
ModingEverett J., et al. “Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.” Cancer Discovery, Vol. 11, No. 12, Dec.1, 2021, pp. 2968–2986, 10.1158/2159-8290.cd-21-0634. Accessed July 6, 2022.
SpoorJonathan, et al. “Liquid Biopsy in Esophageal Cancer: A Case Report of False-Positive Circulating Tumor DNA Detection due to Clonal Hematopoiesis.” Annals of Translational Medicine, Vol. 9, No. 15, Aug.2021, pp. 1264–1264, 10.21037/atm-21-525. Accessed Nov. 21, 2021.
7.
BentAlisha, et al. “The Future of CtDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.” Clinical Colorectal Cancer, Mar.2022, 10.1016/j.clcc.2022.03.004. Accessed May 2, 2022.
